Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/06/2012CN101745111B Method for restraining infiltration and metastasis of breast cancer cells by using target CCL 18 and application thereof
06/06/2012CN101721610B Medicine for treating tumors
06/06/2012CN101703782B Method for preparing nano-prodrug of nucleoside phosphorus acylation coupled chitosan derivative and application thereof
06/06/2012CN101696413B SiRNA-935 capable of inhibiting BCLL11B expression and tumorous T cell proliferation and use thereof
06/06/2012CN101696412B SiRNA-434 capable of inhibiting BCL11B expression and tumorous T cell proliferation and use thereof
06/06/2012CN101679396B Triazolyl aminopyrimidine compounds
06/06/2012CN101663301B Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
06/06/2012CN101657449B Diphenyl-dihydro-imidazopyridinones
06/06/2012CN101585809B Novel compound with antibacterial and antitumor activities
06/06/2012CN101560145B Method for separating chrysophanol and physcion by silica-gel column chromatography
06/06/2012CN101544693B Recombined extrasin alpha 1 two-strand body protein and preparation method thereof
06/06/2012CN101537006B Application of pyridazinone compounds in preparing antitumor drugs
06/06/2012CN101530461B Traditional Chinese medicine for treating nasopharyngeal cancer
06/06/2012CN101528714B Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
06/06/2012CN101524546B Conjugate conjugated from polyethylene glycol and curcumin derivative
06/06/2012CN101522188B Anti-cancer agent
06/06/2012CN101511369B Methods and compositions for inhibiting angiogenesis.
06/06/2012CN101507737B Active components of gallnut and preparation method and use thereof
06/06/2012CN101478960B Compounds A-R-X for the manufacture of pharmaceutical preparations
06/06/2012CN101437834B Modulation of cytokine signaling regulators and applications for immunotherapy
06/06/2012CN101428083B Effective component of cortex dictamni, preparation method and use thereof
06/06/2012CN101417995B Phenoxy pyrimidine derivates and preparation method and use thereof
06/06/2012CN101347534B Effective component of gamene and preparation and use thereof
06/06/2012CN101213192B Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
06/05/2012US8193351 HSP90 inhibitor
06/05/2012US8193332 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
06/05/2012US8193326 Nucleotide sequences coding oncogenic polypeptides for use in generating vaccines to prevent and treat cell proliferative disorders; genetic vaccines
06/05/2012US8193310 Alpha helical mimics, their uses and methods for their production
06/05/2012US8193231 Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
06/05/2012US8193230 Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
06/05/2012US8193229 Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
06/05/2012US8193199 Heterocyclic compounds and their uses
06/05/2012US8193186 Pyridopyrazines and the use thereof as kinase inhibitors
06/05/2012US8193166 Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation
06/05/2012US8193162 Human liver regeneration associated protein and the use thereof
06/05/2012US8192753 pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same
06/05/2012US8192732 Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
06/05/2012CA2661861C Heterocyclic fxr binding compounds
06/05/2012CA2571019C 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
06/05/2012CA2561826C Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody
06/05/2012CA2557275C Bicyclo derivative
06/05/2012CA2520000C Compositions and methods for treating cancer
06/05/2012CA2519113C Antibodies against insulin-like growth factor i receptor and uses thereof
06/05/2012CA2489041C Bafilomycin-like metabolite from a novel micromonospora species
06/05/2012CA2482041C 4-chromanone derivatives for treating cellular proliferative diseases and disorders
06/05/2012CA2475766C Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
06/05/2012CA2435375C Mammalian tumor susceptibility gene products and their uses
06/05/2012CA2397359C Composition of antigen and glycolipid adjuvant sublingual administration
06/05/2012CA2368670C Modulation of vascular permeability by means of tie2 receptor activators
06/05/2012CA2324226C Inhibitors of caspases
06/05/2012CA2292882C Mutant having uracil phosphoribosyl transferase activity
06/05/2012CA2249352C Immunoliposomes that optimize internalization into target cells
06/05/2012CA2248667C Hla-a2.1 binding peptides and their uses
05/2012
05/31/2012WO2012071554A2 Anti-il-6 antibodies for the treatment of oral mucositis
05/31/2012WO2012071501A1 Benzoxazepines asn inhibitors of p13k/m tor and methods of their use and manufacture
05/31/2012WO2012071425A1 Solid state forms of sorafenib besylate, and processes for preparations thereof
05/31/2012WO2012071414A2 Quinoxaline compounds and uses thereof
05/31/2012WO2012071383A2 Methods and compositions to eliminate chronic lymphocytic leukemia and other hematologic malignant cells in stromal microenvironment for cancer therapy
05/31/2012WO2012071336A1 Salts and crystalline forms of an apoptosis-inducing agent
05/31/2012WO2012071276A1 Oncolytic virus as an inducer for innate antitumor immunity
05/31/2012WO2012071269A2 Selective removal of cells having accumulated agents
05/31/2012WO2012071216A2 Antibodies for tumor gangliosides
05/31/2012WO2012070973A1 Method for treating cancer patients
05/31/2012WO2012070970A1 Diagnostic method for predicting the development of cancerous diseases and monitoring treatment efficacy
05/31/2012WO2012070965A1 Modified anticomplementary oligonucleotides with anticancer properties and method for producing same
05/31/2012WO2012070964A1 Modified oligopeptides with anticancer properties and method for producing same
05/31/2012WO2012070905A2 Mollusk extract for preventing or treating rare and intractable diseases of the human body
05/31/2012WO2012070656A1 Process for production of hydroxystilbene derivative having physiological activity
05/31/2012WO2012070649A1 Highly-soluble pyrroloquinoline quinone salt and method for producing same
05/31/2012WO2012070033A1 An implant for the controlled release of pharmaceutically active agents
05/31/2012WO2012070029A1 A pharmaceutical composition
05/31/2012WO2012070024A1 Carbonic anhydrase inhibitors with antimetastatic activity
05/31/2012WO2012069608A1 Technetium-99m complex as a tool for the in vivo diagnosis of cancerous tumours
05/31/2012WO2012069550A1 Novel homogeneous humanized antiproliferation antibodies
05/31/2012WO2012069525A1 Inhibitors of sp140 and their use in therapy
05/31/2012WO2012069410A1 177lutetium-labeled bombesin analogs for radiotherapy
05/31/2012WO2012069402A1 Substituted cyclopentyl - azines as casr- active compounds
05/31/2012WO2012069202A1 Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
05/31/2012WO2012068936A1 Use of hepatocyte nuclear factor 1α in preparation of drug for treating malignant solid tumor disease
05/31/2012WO2012068870A1 Ternary complex, liquid containing ternary complex, preparing method and use thereof
05/31/2012WO2012047017A3 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same
05/31/2012WO2012046943A3 Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence
05/31/2012WO2012030150A3 Composition for preventing and treating prostate cancer containing ailanthus altissima swingle organic solvent extract
05/31/2012WO2012030149A3 Composition for preventing and treating prostate cancer containing caesalpinia sappan l. extract
05/31/2012WO2012030148A3 Composition for preventing and treating prostate cancer including thistle root extract
05/31/2012WO2012030147A3 Composition for treating prostate cancer including tussilago farfara linne extract
05/31/2012WO2012030142A3 Composition for treating prostate cancer including spikenard extract
05/31/2012WO2012027328A3 Anti-ox40 antibodies and methods of using the same
05/31/2012WO2012023811A3 Pharmaceutical composition for suppressing angiogenesis, and method for screening active material for suppressing angiogenesis
05/31/2012WO2012021845A3 Improved hematopoietic stem and progenitor cell therapy
05/31/2012WO2012021486A3 Acylsulfonamides and processes for producing the same
05/31/2012WO2012018877A9 Treating breast cancer with anti-il-19 antibody
05/31/2012WO2012015986A3 Substituted dioxopiperidinyl phthalimide derivatives
05/31/2012WO2012015914A3 Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics
05/31/2012WO2012012772A3 Drug eluting hydrogels for catheter delivery
05/31/2012WO2012008765A3 Pharmaceutical composition for treating or preventing cancer
05/31/2012WO2011156045A3 Tablet formulation of ezatiostat
05/31/2012WO2011143653A3 Recombinant hcmv and rhcmv vectors and uses thereof
05/31/2012WO2011140132A9 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
05/31/2012WO2011135294A8 Method, device and system for targetted cell lysis
1 ... 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 ... 2211